Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LeFuNeng plus capecitabine in advanced colorectal cancer after progression on standard therapy
CTR20140080Phase 2Active
- Sponsor
- Genneva Biopharmaceutical
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of novaferon, capecitabine in colorectal cancer (CRC), sponsored by Genneva Biopharmaceutical. Started May 2014; status: active.
02
Drugs
novaferoncapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20140080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140080.